CoLumboX

CoLumboX is a Class II medical image management and processing software tool designed to assist medical professionals in the review, analysis, and interpretation of previously acquired DICOM lumbar spine X-ray images. It functions by providing functionalities for feature segmentation, measurement, and threshold-based labeling of out-of-range measurements, with its safety and effectiveness demonstrated through software verification, validation testing, and a clinical data-based performance assessment study.

The U.S. Food & Drug Administration (FDA) has authorized Smart Soft Healthcare AD to market its CoLumboX device, classifying it as a Class II medical image management and processing system. This regulatory clearance, issued on May 28, 2025, signifies that CoLumboX has been deemed substantially equivalent to existing marketed devices, contingent upon the manufacturer's adherence to general controls, including annual registration, device listing, good manufacturing practices, and truthful labeling. CoLumboX is a dedicated software tool designed for post-processing and quantitative analysis of previously acquired DICOM lumbar spine X-ray images. It facilitates medical professionals by offering functionalities such as automated feature segmentation, precise measurement capabilities, and threshold-based labeling to highlight out-of-range measurements for review, analysis, and interpretation. Critically, the software is not intended to produce or recommend medical diagnoses or treatments, instead supporting users in identifying and classifying features while reserving medical judgment for the clinician. Smart Soft Healthcare AD demonstrated the device's safety and effectiveness through comprehensive software verification, rigorous validation testing, and a performance assessment study based on clinical data, further obligating the company to comply with additional regulatory requirements like quality system regulations, unique device identification, and medical device reporting for adverse events.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific features does CoLumboX segment and measure on lumbar spine X-rays, and how are these features clinically relevant?; What was the methodology and sample size of the clinical data-based performance assessment study, and what were its key findings regarding the accuracy and precision of measurements?; How were the 'out-of-range' measurement thresholds determined, and what is the clinical sensitivity and specificity of the threshold-based labeling feature?; Does CoLumboX integrate with existing Picture Archiving and Communication Systems (PACS) or Electronic Medical Records (EMR), and what are its technical specifications and system requirements for deployment?; Are there any post-market surveillance plans or ongoing studies to further evaluate the long-term clinical utility and impact of CoLumboX on diagnostic workflows and patient outcomes?